Time to market evaluation for new chemical entities in Italy: a critical analysis of the period 2018-2024

Objective: This study aims to provide an up-to-date analysis, for new chemical entities on the market, on the timing of pricing and reimbursement (P&R) in Italy, covering the entire period of activity (from September 2018 to January 2024) of the last evaluation Commission (Technical Scientific...

Full description

Bibliographic Details
Published in:	Global & Regional Health Technology Assessment
Main Authors:	Alessandro Tedesco, Marzia Bonfanti, Asia Barugolo, Fulvio Luccini, Patrizia Berto
Format:	Article
Language:	English
Published:	AboutScience Srl 2025-05-01
Subjects:	Italy Orphan drugs Pricing Rare diseases Time-to-market
Online Access:	https://journals.aboutscience.eu/index.php/grhta/article/view/3422

Similar Items

Variables affecting pricing of orphan drugs: the Italian case
by: Claudio Jommi, et al.
Published: (2021-10-01)

The actual status of drug prices and adjustment factors for drug price calculation: an analysis of ultra-orphan drug development in Japan
by: Akihiko Kawakami, et al.
Published: (2022-11-01)

A comparative study of orphan drug prices in Europe
by: Katherine Eve Young, et al.
Published: (2017-01-01)

Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe
by: Goran Medic, et al.
Published: (2017-01-01)

Determinants of orphan drugs prices in France: a regression analysis
by: Daria Korchagina, et al.
Published: (2017-04-01)

The length of price&reimbursement negotiation procedures in Italy in the period 2021-2023 was independent from the price of medicines
by: Raffaella Cocciolo, et al.
Published: (2025-01-01)

Analysis of patient access to orphan drugs in Turkey
by: Güvenç Koçkaya, et al.
Published: (2021-02-01)

Cross-national comparative study of orphan drug policies in Saudi Arabia, the United States, and the European Union
by: Bander Balkhi, et al.
Published: (2023-09-01)

Trends in orphan medicinal products approvals in the European Union between 2010–2022
by: Luísa Bouwman, et al.
Published: (2024-02-01)

Practice of the Qualification and Recognition for Orphan Drugs in the World and its Inspiration
by: ZHU Xiaohong, et al.
Published: (2022-07-01)

Analysis of the number of registered patients whis rare diseases in some regions of Ukraine
by: M. V. Podgaina, et al.
Published: (2021-12-01)

Determinants of orphan drug health technology assessment in South Korea: an empirical analysis
by: Se Hee Lee, et al.
Published: (2025-09-01)

Utilization and affordability of health insurance coverage for rare disease drugs in a first-tier city in Northeast China from 2018 to 2021: a study based on the health insurance claims database
by: Yaqun Wang, et al.
Published: (2024-07-01)

Current Problems in Provision of Orphan Drugs and Ways to Solve Them
by: Alexei S. Kolbin, et al.
Published: (2016-09-01)

Current Status of Drug Development and Implementation for Diseases Included in the Second Catalog of Rare Diseases
by: LI Kexin, et al.
Published: (2023-10-01)

Are payers treating orphan drugs differently?
by: Joshua P. Cohen, et al.
Published: (2014-01-01)

Orphan drugs in Italy: availability and time-to-access at regional level
by: Maria Lucia Marino, et al.
Published: (2023-12-01)

EMA approved orphan medicines since the implementation of the orphan legislation
by: Eveliina Hahl, et al.
Published: (2025-06-01)

Visual Research of Global Orphan Drug from a Bibliometric Perspective
by: Wen X, et al.
Published: (2025-05-01)

« Orphans ». Hyponym for rare diseases, but not so ultra-rare.
by: Nor El Houda KHELIF, et al.
Published: (2025-06-01)

Rare diseases: What rheumatologists need to know?
by: Renan Rodrigues Neves Ribeiro do Nascimento, et al.
Published: (2024-09-01)

Generic orphan drug substitution: a critical analysis of global practices and Saudi Arabia’s perspective
by: Yousif S. Alakeel, et al.
Published: (2024-04-01)

Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada
by: Fernanda Naomi Inagaki Nagase, et al.
Published: (2019-06-01)

Features of intellectual property protection mechanisms on the example of orphan drugs circulation
by: D. S. Yurochkin, et al.
Published: (2022-01-01)

Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen
by: Viviana Giannuzzi, et al.
Published: (2017-04-01)

Pricing Zolgensma – the world’s most expensive drug
by: Mark Nuijten
Published: (2022-12-01)

Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019
by: Xavier Badia, et al.
Published: (2020-08-01)

The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change
by: K. E. Young, et al.
Published: (2017-01-01)

Price and reimbursement of medicines when new indications are approved: the results of a survey on ISPOR Italy Rome Chapter members
by: Claudio Jommi, et al.
Published: (2023-05-01)

Current Status and Prospect of Orphan Drugs for Rare Skin Diseases in China
by: ZHANG Shan, et al.
Published: (2023-04-01)

Economic development and the growth of the trade sector in Italy
by: R.H. HOLTON
Published: (2014-03-01)

What is the awareness of rare diseases among medical students? A survey in Bulgaria
by: Eleonora Hristova-Atanasova, et al.
Published: (2023-07-01)

Historical and projected public spending on drugs for rare diseases in Canada between 2010 and 2025
by: Richard Lech, et al.
Published: (2022-10-01)

Prices, distribution and investment in Italy 1951-1966: an interpretation
by: P. SYLOS LABINI
Published: (2014-03-01)

Study on Drug List and Accessibility of Rare Diseases Based on the China′s Second List of Rare Diseases
by: LIU Qingyang, et al.
Published: (2024-04-01)

Research of Accessibility of Rare Disease Drugs Based on the China's First List of Rare Diseases
by: LIU Qingyang, et al.
Published: (2023-11-01)

Overview and Analysis of Rare Disease Drugs Approved for Market in China, the United States, the European Union, and Japan in 2023
by: WANG Shaohong, et al.
Published: (2024-04-01)

Clinical trials and the importance of biobanks in rare diseases
by: Nežić Lana, et al.
Published: (2018-01-01)

Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs—a Systematic Literature Review. Next Steps in Methodology Development?
by: Aleksandra Baran-Kooiker, et al.
Published: (2018-10-01)

Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases
by: V. Vanhoorne, et al.
Published: (2019-08-01)